Loading...
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...
Saved in:
| Published in: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5684255/ https://ncbi.nlm.nih.gov/pubmed/28656543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0528-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|